The industry awaits a number of readouts and approvals for drugs that address market gaps and enrich treatment landscapes — with huge sales potential to boot.
Pfizer punts on one oral GLP-1 candidate, advances another
Eplontersen, which is being examined for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy, met all of its co-primary endpoints.
Pipeline Report 2022: Patient experience takes center stage
The past two years were all about COVID-19 vaccines and therapeutics. Now, imminent approvals in oncology, hematology and autoimmune disorders are set to enhance patient convenience.
Novo Nordisk diabetes pill delivers in late-stage trial; Gilead partners with Sangamo on engineered cell therapies; Study finds antidepressants work, though with varying results.
Loading...
MM+M Transform: The Patient, Provider and Payer Engagement Matrix